| Nov 2 |
Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank
|
| Nov 1 |
Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium
|
| Nov 1 |
Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
|
| Nov 1 |
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
|
| Nov 1 |
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
|
| Nov 1 |
Stocks to watch next week: Berkshire Hathaway, Super Micro, Novo Nordisk, Vistry and M&S
|
| Nov 1 |
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News
|
| Nov 1 |
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
|
| Nov 1 |
Eli Lilly and Company Just Missed Earnings - But Analysts Have Updated Their Models
|
| Nov 1 |
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
|
